VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2022 | Open-label TERIKIDS extension: teriflunomide in pediatric MS

Compared with adults with multiple sclerosis (MS), pediatric patients often have higher relapses, a greater MRI lesion burden, and a slower rate of accrual of permanent neurological disability. Treatment options for pediatric patients with relapsing form of MS (RMS) are limited. In the 2-year, randomized Phase III TERIKIDS trial (NCT02201108) of pediatric patients with RMS, teriflunomide reduced relapse risk and significantly reduced new/enlarging T2 and gadolinium-enhancing T1 lesion counts versus placebo. Kumaran Deiva, MD, PhD, Faculty of Medicine Paris Sud, Paris, France, discusses the results from the open-label TERIKIDS extension trial. During the open-label periods, teriflunomide had beneficial effects in pediatric patients with RMS, similar to those seen in adults. Teriflunomide reduced the risk of clinical relapses, sustained disability progression, and MRI lesions with a manageable safety profile. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.

Transcript (edited for clarity)

Yeah, teriflunomide has been already approved in adults. So we have performed a study in children with that treatment in order to see the efficacy, the pharmacokinetics, and also the safety profile of the treatment. What the study adds is that the efficacy seems to be similar to what has been seen in adults and specifically on MRI activity, which is really significant. The safety profile seems also to be good and similar to what has been seen in adults...

Yeah, teriflunomide has been already approved in adults. So we have performed a study in children with that treatment in order to see the efficacy, the pharmacokinetics, and also the safety profile of the treatment. What the study adds is that the efficacy seems to be similar to what has been seen in adults and specifically on MRI activity, which is really significant. The safety profile seems also to be good and similar to what has been seen in adults. In children, the treatment availabilities are very low, as we can’t perform lot of studies in children. So this study has given us the opportunity to use teriflunomide in children with multiple sclerosis, actually. So these kind of studies are needed to improve the availability of these treatments in children.

Read more...